Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants.

MLA

Li, Zonglin, et al. “Dipeptidyl Peptidase 4-Inhibitor Treatment Was Associated with a Reduced Incidence of Neoplasm in Patients with Type 2 Diabetes: A Meta-Analysis of 115 Randomized Controlled Trials with 121961 Participants.” Expert Opinion on Investigational Drugs, vol. 31, no. 9, Sept. 2022, pp. 957–64. EBSCOhost, https://doi.org/10.1080/13543784.2022.2113056.

APA

Li, Z., Lin, C., Zhou, J., Cai, X., Zhu, X., Hu, S., Lv, F., Yang, W., & Ji, L. (2022). Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants. Expert Opinion on Investigational Drugs, 31(9), 957–964. https://doi.org/10.1080/13543784.2022.2113056

Chicago

Li, Zonglin, Chu Lin, Jinyu Zhou, Xiaoling Cai, Xingyun Zhu, Suiyuan Hu, Fang Lv, Wenjia Yang, and Linong Ji. 2022. “Dipeptidyl Peptidase 4-Inhibitor Treatment Was Associated with a Reduced Incidence of Neoplasm in Patients with Type 2 Diabetes: A Meta-Analysis of 115 Randomized Controlled Trials with 121961 Participants.” Expert Opinion on Investigational Drugs 31 (9): 957–64. doi:10.1080/13543784.2022.2113056.